13 results about "Antihistamine" patented technology

Described herein are compositions and methods for treating or preventing skin or ocular surface disorders, such as those associated with bacterial and / or parasitic infections. Bacterial and / or parasitic infections include mites (e.g., Demodex), helminths, protozoa (e.g., amebas (e.g., Acanthamoeba or Cryptosporidiosis)), onchocerciasis, lice, scabies, nematodes, or chlamydia. The compositions and methods include compounds that exhibit immunological activity, keratolytic activity, antihistamine activity, anti-inflammatory activity, and / or other desirable activities. Topical administration of the compositions to the eyelid margin or surrounding area provides therapeutic benefit to patients with ocular surface disorders.

An antihistamine compound having the structure of formula (I), a pharmaceutically acceptable salt thereof, a method for preparing the same, and use of the antihistamine compound having the structure of formula (I) and a pharmaceutically acceptable salt thereof in the treatment of diseases such as seasonal / perennial allergic rhinitis, allergic conjunctivitis, and urticaria. JPEG2025519827000061.jpg85170

The present invention relates to an aqueous pharmaceutical composition for injection comprising doxylamine or a physiologically acceptable salt thereof wherein the concentration of doxylamine is in the range of from 5 mg / ml to 25 mg / ml, based on the weight of doxylamine free base and based on the total volume of the composition; wherein the pH value of the composition is in the range of 6.0 to 7.0. The pharmaceutical composition disclosed by the invention has the effects and effects of sedation, hypnosis, histamine resistance, choline resistance, allergy resistance and the like.

This invention relates to the use of ingredients comprising paracetamol, ibuprofen, and any one or both of antihistamine and guaifenesin (or a pharmaceutically acceptable salt, metabolite, or enantiomer of any mentioned aforesaid) in the production of a medication for the treatment of any one or more of mucosal congestion, coughing, fever, sinus secretions, muscle ache, malaise, cold, flu and headache in a human.

Provided is a means for shortening the onset time of the action of a local anesthetic, an antihistamine, or the like in the oral mucosa. The micro-protrusion patch comprises a base plate and micro-protrusions erected on the base plate, and the micro-protrusion patch is made of water-insoluble thermoplastic polymer materials and used for being applied to oral mucosa. And a topical application system comprising the microprotrusion patch, a coating drug (a gel or ointment containing the drug, etc.), and an adhesive tape for backing, for shortening the action time of the drug in the oral mucosa.

The invention belongs to the technical field of chemical synthesis of medicines, and particularly relates to a preparation process of azelastine hydrochloride, which comprises four steps of condensation reduction, hydrochloric acid hydrolysis, cyclization and hydrochloric acid salification. According to the method, the reaction efficiency, the product yield and the purity are improved, the production cost and the operation difficulty are reduced, and a stable, cost-controllable and repeatable preparation process is formed. The prepared azelastine hydrochloride is a long-acting anti-allergic drug, has dual effects of resisting histamine and inflammation, has high affinity to a receptor, effectively blocks histamine release of mast cells and basic granulocytes, has wide pharmacological effects on leukotriene, kinin, platelet activating factors and other inflammatory chemical mediators, and can be used for preparing an anti-allergic drug. Therefore, azelastine can effectively relieve typical symptoms of allergic conjunctivitis, such as pruritus, conjunctival congestion, lacrimation, conjunctival edema and the like.

The present invention relates to a renal disease treatment effect obtained by the co-administration of desloratadine, which is an antihistamine, and duloxetine, which is a serotonin reuptake inhibitor. It has been identified that, when desloratadine and duloxetine are co-administered, the formation and growth of cysts were inhibited in an ADPKD animal model, the renal function was also maintained at a normal value, liver cysts and liver fibrosis caused by ADPKD were treated, renal fibrosis was significantly treated in in vitro and animal renal fibrosis models, and, in particular, the effects were synergistically increased.

This disclosure relates to compositions for treating skin conditions and improving skin health. In particular, the disclosure relates to compositions formulated as an absorbent article to be topically applied to skin, the absorbent article comprising an analgesic agent, antihistamine agent and / or a corticosteroid.

The invention discloses a skin antibacterial and antipruritic pharmaceutical composition containing plant extracts and a preparation method thereof, the skin antibacterial and antipruritic pharmaceutical composition containing the plant extracts comprises the following components: at least two of the plant extracts selected from honeysuckle extracts, mint extracts, tea tree oil extracts and aloe extracts, an antibacterial agent selected from a natural antibacterial agent or a synthetic antibacterial and antipruritic agent, and a preservative selected from a natural antibacterial agent or a synthetic antibacterial and antipruritic agent. The invention relates to an anti-pruritic composition, which is prepared from an antihistamine agent or a natural anti-pruritic component, a carrier, a water-based gel, a cream or an oily substrate, and an additional additive, which is prepared from a humectant, a preservative and a pH (Potential of Hydrogen) regulator. During implementation, by optimizing the selection and proportion of the plant extracts and combining specific carriers and auxiliary components, the antibacterial and antipruritic effects are remarkably improved, and meanwhile, the side effect risk is reduced. According to the composition, the synergistic effect of various plant extracts is utilized, the skin permeability and durability are enhanced, and the composition is suitable for various skin problems such as eczema, dermatitis and mosquito bites. The preparation method is simple and efficient, is easy for industrial production, and has a wide market application prospect.

The present disclosure provides compositions, uses thereof, and methods for treating subjects with obesity and / or metabolic disorders. In aspects and embodiments, the method comprises administering an effective amount of one or more of a mast cell stabilizer and an H1-antihistamine, in combination with a non-steroidal anti-inflammatory drug (NSAID), either in the same or separate compositions.

Disclosed herein are methods of administering a Casitas B-lineage lymphoma proto-oncogene B inhibitor (CBL-Bi) for treating a cancer in a subject. Additionally disclosed herein are methods of administering a pre-treatment in combination with the CBL-Bi for treating a cancer in a subject.

The invention discloses a lactobacillus gasseri BDUP (Lactobacillus gasseri) strain and application of the lactobacillus gasseri BDUP strain in preparation of drugs for treating atopic dermatitis or eczema. The preservation number of the lactobacillus gasseri BDUP strain is CGMCC (China General Microbiological Culture Collection Center) No. 18357. Different from existing probiotics which take effect mainly by resisting histamine or regulating Th1 / Th2 balance, the invention discloses a unique nerve-immune bidirectional regulation mechanism of the BDUP strain for the first time, and the BDUP strain can significantly down-regulate expression levels of a neuropeptide P substance (Substance P), a calcitonin gene-related peptide (CGRP), a nerve growth factor (NGF) and a pruritus specific factor IL-31 in skin tissues, so that the BDUP strain can be used for treating skin pruritus. Therefore, neurogenic inflammation and a pruritus conduction pathway are effectively blocked. Animal experiments show that the BDUP strain can shorten the scratching time of eczema model mice by about 80%, the itching relieving and anti-inflammatory effects of the BDUP strain are equivalent to those of potent glucocorticoid, and the BDUP strain has no side effect. The invention provides a novel efficient biological treatment scheme for solving intractable pruritus caused by eczema.

The present invention is a method for improving atopic dermatitis, comprising administering to a subject in need thereof a composition comprising a low-molecular-weight fucoidan (LMF), wherein the weight-average molecular weight of the LMF is less than 3,000 Daltons. The composition of the present invention can effectively improve the area and severity of the lesion in patients with AD, as well as the itching symptoms (including insomnia symptoms caused by itching), and can significantly improve the SCORAD index of patients with AD. In addition, the composition of the present invention can reduce the patient's dependence on topical steroid ointments and / or oral antihistamines and reduce the AD-related immune parameters without increasing the biochemical indices of liver and kidney. Therefore, the composition of the present invention can be both effective and safe in the treatment of AD.